Company intelligence / Profile preview

Actamax Surgical Materials

Berkeley, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~2
Development stage: Phase 1

Overview

A first-in-human randomized controlled trial demonstrated that the sprayable degradable hydrogel adhesion barrier was safe, easy to use, and effective at reducing postoperative adhesions—showing a 41.4% reduction overall and nearly 50% reduction following myomectomy compared with controls. No serious or device-related adverse events were reported.

Therapeutic areas: Women's Health
Modalities: DeviceHydrogel-based drug delivery therapyPolymer-drug conjugate therapy
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Actamax Adhesion Barrier

Phase 1

Indications: Post-surgical adhesions

Partnerships

DuPontDSM Biomedical

Beyond the preview

Go deeper on Actamax Surgical Materials.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actamax Surgical Materials.

Explore the full profile